Figure 3
From: Metformin ameliorates the severity of experimental Alport syndrome
Metformin regulates various intracellular signaling pathways in kidney of Col4a5 G5X Alport syndrome mice. (a) Whole kidney lysates were analyzed by immunoblotting. The full-length blots are presented in Supplementary Fig. S12. (b–h) The relative amount of proteins was quantified. Losartan or metformin decreased the level of (c) phospho-p38, (d) phospho-STAT3, (e) phospho-mTOR. Only metformin increased the level of (a) phospho-AMPK, (f) phospho-ERK, (g) phospho-p53 and (h) Nrf2. Data are expressed as the means ± S.E. (n = 4 per group). P values were assessed by Dunnett’s test (*P < 0.05, **P < 0.01 vs vehicle).
